Skip to content
Screener

CRISPR Therapeutics CRSP Other Non-Current Liabilities

Other Non-Current Liabilities at other companies

Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$41M+136%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
$16.12M+43.0%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$305K-26.3%
Sana Biotechnology logo
Sana BiotechnologySANA
$9.81M+3.8%
Regenxbio logo
RegenxbioRGNX
$486K-26.8%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$1.83M+51.6%

Other financials

Income statement

See full
Revenue$1.5M+68.6%
Operating income-$130.2M+12.2%
Net income-$122.9M+9.6%
EPS (diluted)-$1.28+19.0%

Balance sheet

See full
Cash & equivalents$423.3M+80.0%
Total debt$787.6M+259%
Total equity$1.8B-0.8%
Total assets$2.7B+25.8%

Cash flow

See full
Operating cash flow-$108.9M-102%
CapEx$504.0K+145%
Free cash flow-$109.4M-102%

Valuation

See full
Market cap$4.99B-2.6%
Enterprise value$5.36B+4.1%
P/S1,217×+1,082×

Profitability

See full
Operating margin-15,754.2%-17,253pp
Net margin-13,856.5%-15,058pp
FCF margin-9,777.6%-10,759pp

Returns & leverage

See full
Return on equity-31.2%+43.7pp
Debt / equity0.4×+0.3×
Current ratio18×+2.3×

Where this comes from

Reported directly by CRISPR Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.

The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:48 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-204188
Line itemAs of / March 31, 2026As of / December 31, 2025
Total current liabilities136,286149,120
Long-term debt585,470—
Operating lease liabilities, net of current portion183,560188,168
Other non-current liabilities5,9486,142
Total liabilities911,264343,430
Commitments and contingencies, see Note 7
Shareholders’ equity:
Common shares, CHF 0.03 nominal value, 132,477,166 shares authorized at March 31, 2026 and at December 31, 2025, 96,500,822 and 96,009,657 shares issued at March 31, 2026 and December 31, 2025, respectively, 96,385,506 and 95,894,341 shares outstanding at March 31, 2026 and December 31, 2025, respectively3,1153,087

Item 1. Financial Statements

FAQ

What is CRISPR Therapeutics's other non-current liabilities?
CRISPR Therapeutics (CRSP) reported other non-current liabilities of $5.95M in Q1 2026.
How has CRISPR Therapeutics's other non-current liabilities changed year-over-year?
CRISPR Therapeutics's other non-current liabilities increased by 79.2% year-over-year, from $3.32M to $5.95M.
What is the long-term trend for CRISPR Therapeutics's other non-current liabilities?
Over 5 years (2020 to 2025), CRISPR Therapeutics's other non-current liabilities has grown at a -4.2% compound annual growth rate (CAGR), from $7.63M to $6.14M.
What does other non-current liabilities mean?
Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.

Ask your AI about CRISPR Therapeutics's other non-current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude